

## Andy Sewell

Title: Discovery of new broadly-expressed tumour antigens and new modes of T-cell recognition by dissection of successful Scandinavian cancer immunotherapy

Abstract: Tumour infiltrating lymphocyte (TIL) therapy involves expanding TIL from a tumour lesion *in vitro* to large numbers prior to adoptive transfer into patient blood. TIL therapy results in tumour regression in the majority of end-stage melanoma patients with a complete lasting remission (cure) in >20% of patients. We have discovered new modes of HLA-restricted and HLA-agnostic T-cell recognition using two new technologies to reveal the ligands recognised by TIL-derived T-cells that persist in patient blood after complete remission. Surprisingly, many of these T-cells can recognise most types of cancer, thereby providing options for future broad-spectrum cancer immunotherapies.

Affiliation: Cardiff University, Cardiff, UK